About Collaborative Drug Discovery
Collaborative Drug Discovery, Inc. (CDD) is the world's first platform for selectively sharing collaborative drug discovery data. Scientists working with the CDD community platform can pool their research in order to more effectively develop new drug candidates for commercial and humanitarian markets. CDD is based in Burlingame, California (15 miles south of San Francisco). The company has provided software and custom services to academic, foundation, and corporate clients since 2004. The CDD global community includes hundreds of scientists from leading research foundations, academia and industry. A subset of the data is available openly to the public at no cost.
Compete with Collaborative Drug Discovery?
Ensure that your company and products are accurately represented on our platform.
Collaborative Drug Discovery's Products & Differentiators
CDD Vault is a complete informatics platform hosted through an intuitive interface. It helps project teams manage, analyze, and present data for biotech companies, CROs, academic labs, research hospitals, agrochemical and consumer goods companies.
Expert Collections containing Collaborative Drug Discovery
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Collaborative Drug Discovery is included in 1 Expert Collection, including Biopharma Tech.
Collaborative Drug Discovery Patents
Collaborative Drug Discovery has filed 1 patent.
Computer memory, Data management, Business intelligence, Data modeling, User interfaces
Computer memory, Data management, Business intelligence, Data modeling, User interfaces
Latest Collaborative Drug Discovery News
Mar 24, 2022
Seoul and Burlingame, CA /PRNewswire/ - Arum Therapeutics Inc. (Arum), a leading pharmaceutical company that specializes in the discovery of new molecules and molecule combinations to target novel oncology announced today that it had implemented CDD Vault , a research data management platform developed by Collaborative Drug Discovery, Inc. (CDD), in its laboratories in Gangseo-gu, Seoul. Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers. The company exploits the concept of synthetic lethality targeting DNA Damage Response (DDR) pathways with the aim of blocking the cancer cell's primary and backup repair mechanisms, thus making it unable to survive. Additional pipelines in oncotargets complement the company's robust pipeline in this area. "At Arum, we are focused on treating cancers where conventional therapies are no longer effective. We have a unique approach that requires effective and secure data management and found that CDD Vault fulfils those requirements. We can easily access and navigate data in an intuitive way which allows us to be more productive", said Taegon Baik, CEO at Arum Therapeutics, "We fully expect the platform to grow with us as we expand the company and move our pipeline downstream." Arum's research data is stored, managed, and analysed in CDD Vault, a hosted informatics platform designed to handle drug discovery data and facilitate secure collaborations. The versatility of CDD Vault allows Arum to organise chemical, biological, and even mixture entities, as well as associated experiment protocols and results. "We are delighted to see Arum make use of CDD Vault's unique capabilities to gain insights from multiple data types and collaborate across disciplines," said Barry Bunin, CEO of CDD, "It is a true pleasure to support Arum's growth and expansion. Their novel approach to target drug-resistant cancer brings hope to millions of patients around the world." About Arum Therapeutics Inc. Arum Therapeutics ( https://arumtherapeutics.com ) is a leading pharmaceutical company that has strength in medicinal chemistry based on synthetic small molecules. The company develops novel anticancer agents to overcome current drug resistance using a platform for synthetic lethality (SL) target associated with the DNA damage response (DDR) mechanisms. The company is based in Seoul, South Korea. About Collaborative Drug Discovery, Inc. CDD's ( www.collaborativedrug.com ) flagship product, "CDD Vault", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for securely managing and sharing biological and chemical data. It lest you intuitively organise chemical structures and biological study data and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN. Source: Collaborative Drug Discovery
Collaborative Drug Discovery Web Traffic
Collaborative Drug Discovery Rank
Collaborative Drug Discovery Frequently Asked Questions (FAQ)
When was Collaborative Drug Discovery founded?
Collaborative Drug Discovery was founded in 2004.
Where is Collaborative Drug Discovery's headquarters?
Collaborative Drug Discovery's headquarters is located at 4171 George Ave., San Mateo.
What is Collaborative Drug Discovery's latest funding round?
Collaborative Drug Discovery's latest funding round is Loan.
How much did Collaborative Drug Discovery raise?
Collaborative Drug Discovery raised a total of $5.78M.
Who are the investors of Collaborative Drug Discovery?
Investors of Collaborative Drug Discovery include Paycheck Protection Program, Omidyar Network and Founders Fund.
Who are Collaborative Drug Discovery's competitors?
Competitors of Collaborative Drug Discovery include Dotmatics (acquired by Insightful Science) and 3 more.
What products does Collaborative Drug Discovery offer?
Collaborative Drug Discovery's products include CDD Vault and 2 more.
Who are Collaborative Drug Discovery's customers?
Customers of Collaborative Drug Discovery include Plexium, MoA Technologies and Standigm.
Compare Collaborative Drug Discovery to Competitors
Sapio Sciences specializes in Laboratory Information Management System Software which allows scientists to quickly configure the LIMS to their requirement.Sapio markets the Exemplar product line which includes laboratory information management (LIMS), electronic laboratory notebook (ELN), molecular diagnostics (MDx), biomarker discovery and data management in a single platform.
Uncountable accelerates R&D for materials and chemical companies with an AI-powered web platform to store and organize experiment data. The Uncountable Platform brings together all R&D data in one place for scientists to access and custom algorithms can suggest formulations to test - enabling complicated development projects to be tackled with less than half the resources.
L7 Informatics develops an end-to-end platform for precision healthcare. The company's Enterprise Science Platform (L7|ESP) is a regulatory compliant platform designed to manage the complexities of precision healthcare across scientific research, diagnostics, therapeutics, and medicine. The platform has native applications including LIMS, ELN, MES, and inventory; can integrate with existing third-party applications, lab instruments, and devices to capture all data in a single data model; and has a low-code/no-code workflow designer and hundreds of pre-built connectors to enable rapid time to value and end-to-end automation. L7 Informatics serves modern life sciences and healthcare organizations. The company was formerly known as Lab7 Systems. It was founded in 2013 and is based in Austin, Texas.
GraphPad is dedicated to creating software exclusively for the international scientific community. Created by scientists for scientists, our intuitive programs provide researchers worldwide with the tools they need to simplify data analysis, statistics and graphing.
Synthace aims to raise universal bioscience productivity, enabling people to better engineer biology for health, food, energy and manufacturing. Central to its technology is Antha, an operating system for biology that enables ease of designing and optimizing biological unit operations that are linked into executable workflows that are reliable, shareable and saleable.
Benchsci is a platform that extracts usage evidence from scientific papers and organizes it around antibodies. BenchSci's first product is its AI-assisted antibody selection platform, which addresses the roughly 50% of research antibodies that simply don't work in experiments. Using data sources along with biologist-trained machine learning models and bioinformatics ontologies, the platform allows scientists to select the right antibodies for their experiments faster.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.